Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Borislav Mihov"'
Autor:
Maria-Antonietta D’Agostino, Tuhina Neogi, Hilde Berner Hammer, Lene Terslev, Lisa Stamp, Tony Merriman, Sarah Stewart, Nicola Dalbeth, Anne Horne, John D Fitzgerald, Mariano Andrés, Tristan Pascart, Janitzia Vázquez-Mellado, Greg Gamble, William Taylor, Julia Martin, Changgui Li, Borislav Mihov, Mingshu Sun, Eleonora Norkuviene, Isabel Su, Maria-Luisa Peral-Garrido, Tillman Uhlig
Publikováno v:
BMJ Open, Vol 14, Iss 11 (2024)
Introduction The central biochemical cause of gout is hyperuricemia (elevated serum urate levels). Ultrasound features of monosodium urate (MSU) crystal deposition are common in people with asymptomatic hyperuricemia. However, it is unclear whether t
Externí odkaz:
https://doaj.org/article/c7bf9cd82f1c4b178d759a3ac08825e9
Autor:
Nicola Dalbeth, Borislav Mihov, Angela Stewart, Gregory D. Gamble, Tony R. Merriman, David Mount, Ian R. Reid, Lisa K. Stamp, Anne Horne
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract In observational studies, serum urate positively associates with cardiometabolic and kidney diseases. We analyzed data from a randomised placebo-controlled trial to determine whether moderate hyperuricemia induced by inosine affects cardiome
Externí odkaz:
https://doaj.org/article/aaf221767c35411ea02839fd3cee2b47
Publikováno v:
Journal of Bone and Mineral Research. 37:2149-2155
Vertebral fractures are associated with height loss, reduced quality of life, and increased mortality and are an important endpoint for osteoporosis trials. However, height loss is associated with quality of life and mortality independent of associat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::069a3f481db93104c606d0fe24ab7a6a
https://doi.org/10.1002/jbmr.4684
https://doi.org/10.1002/jbmr.4684
Autor:
Rachel Murdoch, Borislav Mihov, Anne M. Horne, Keith J. Petrie, Gregory D. Gamble, Nicola Dalbeth
Publikováno v:
Arthritis Care & Research.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fd63efc39482e4501875164a6452d4d
https://doi.org/10.1002/acr.25130
https://doi.org/10.1002/acr.25130
Publikováno v:
Journal of Bone and Mineral Research. 37:3-11
Intravenous zoledronate reduces fracture risk (5 mg at 18-month intervals) and prevents bone loss (doses of 1 to 5 mg for 3 to >5 years), but the duration of action of a single 5 mg dose and the effects of lower doses beyond 5 years are unknown. We r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cfa3bfec52f39aa1a1feed70acd3ca1
https://doi.org/10.1002/jbmr.4453
https://doi.org/10.1002/jbmr.4453
Publikováno v:
Calcified Tissue International. 109:12-16
A recent observational study of the incidence of pneumonia in patients with previous hip fractures found that bisphosphonate use reduced pneumonia risk by about one-quarter, in comparisons with those either not receiving osteoporosis treatment or rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::405f284261e107e7fc5a3eae22985f7d
https://doi.org/10.1007/s00223-021-00830-7
https://doi.org/10.1007/s00223-021-00830-7
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 105:e1641-e1647
Context Intravenous zoledronate prevents bone loss and reduces fracture risk in older adults but the optimal dosing strategy required to achieve each outcome is not known. Objective To assess the effect of very infrequent zoledronate therapy on bone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d69b602e62195cc19f953a8fe8e75c78
https://doi.org/10.1210/clinem/dgaa062
https://doi.org/10.1210/clinem/dgaa062
Autor:
Nicola Dalbeth, Anthony J. Doyle, Karen Billington, Greg D. Gamble, Paul Tan, Kieran Latto, Thrishila Parshu Ram, Ravi Narang, Rachel Murdoch, David Bursill, Borislav Mihov, Lisa K. Stamp, Anne Horne
Publikováno v:
Arthritisrheumatology (Hoboken, N.J.)REFERENCES. 74(6)
To determine whether a therapeutic approach of intensive serum urate lowering results in improved bone erosion scores in patients with erosive gout.We undertook a 2-year, double-blind randomized controlled trial of 104 participants with erosive gout
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1e5c0b32a7442db967325d2807d35aa
https://pubmed.ncbi.nlm.nih.gov/34927391
https://pubmed.ncbi.nlm.nih.gov/34927391
Autor:
Isabel Su, Graham Hosie, Sarah Stewart, Gregory D. Gamble, Nicola Dalbeth, Angelo L. Gaffo, William J. Taylor, Jeremy Holyer, Anne Horne, Borislav Mihov
Publikováno v:
The Journal of rheumatology. 49(2)
ObjectiveSeveral factors contribute to the patient experience of gout flares, including pain intensity, duration, frequency, and disability. It is unknown which of these factors are most important to patients when considering flare burden over time,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72a75a803dc6be6f45932fa98feb5de0
https://pubmed.ncbi.nlm.nih.gov/34725178
https://pubmed.ncbi.nlm.nih.gov/34725178